Circular RNA circ-LDLRAD3 as a biomarker in diagnosis of pancreatic cancer

Table 1 Clinicopathological factors of patients’ tissue samples and expression of circ-LDLRAD3 in pancreatic cancer

Characteristic	n (%)
Age (yr)
≥ 60	19 (63.3)
< 60	11 (36.7)
Gender
Male	9 (30)
Female	21 (70)
Tumor diameter (cm)
≤ 4	19 (63.3)
> 4	11 (36.7)
CA19-9
Positive	19 (63.3)
Negative	11 (36.7)
CEA
Positive	16 (56.7)
Negative	13 (43.3)
Clinical stage
IA	3 (10)
IB	10 (33.3)
IIA	7 (23.3)
IIB	9 (30)
III	1 (3.3)
IV	0 (0)
T classification
T1	3 (10)
T2	15 (50)
T3	11 (36.7)
T4	1 (3.3)
N classification
N0	20 (66.7)
N1	10 (33.3)
N2	0 (0)
Metastasis
M0	30 (100)
M1	0 (0)
Venous invasion
No	24 (80)
Yes	6 (20)
Lymphatic invasion
No	23 (76.7)
Yes	7 (23.3)
Expression of circ-LDLRAD3
Low expression	12 (40)
High expression	18 (60)

Table 2 Correlation between circ-LDLRAD3 expression and clinicopathological factors of pancreatic cancer patients (tissue samples)

Characteristic	Circ-LDLRAD3		P value
	Low or none, n	High, n
Age (yr)
≥ 60	9	10	0.279
< 60	3	8
Gender
Male	7	14	0.255
Female	5	4
Tumor diameter (cm)
≤ 4	9	10	0.279
> 4	3	8
CA19-9
Positive	5	6	0.643
Negative	7	12
CEA
Positive	5	8	0.88
Negative	7	10
Clinical stage
IA	2	1	0.256
IB	6	4
IIA	1	6
IIB	3	6
III	0	1
IV	0	0
T classification
T1	2	1	0.274
T2	8	8
T3	2	8
T4	0	1
N classification
N0	9	11	0.429
N1	3	7
N2	0	0
Metastasis
M0	12	18	None
M1	0	0
Venous invasion
No	12	12	0.025
Yes	0	6
Lymphatic invasion
No	12	11	0.014
Yes	0	7

Table 3 Spearman analysis of correlation between circ-LDLRAD3 and clinicopathological factors of pancreatic cancer patients (ΔCT values in tissues)

Variable	Circ-LDLRAD3 expression level
	Spearman correlation	P value
Age (yr)	-0.22	0.243
Gender	-0.122	0.521
Tumor diameter (cm)	-0.303	0.104
CA19-9	0.028	0.883
CEA	0.019	0.919
Clinical stage	-0.415	0.022
T classification	-0.519	0.003
N classification	-0.196	0.299
Metastasis	None	None
Venous invasion	-0.607	< 0.001
Lymphatic invasion	-0.478	0.008

Table 4 Clinicopathological factors of plasma samples of patients with pancreatic cancer and expression of circ-LDLRAD3

Characteristic	n (%)
Age (yr)
≥ 60	15 (48.4)
< 60	16 (51.6)
Gender
Male	19 (61.3)
Female	12 (38.7)
Tumor diameter (cm)
≤ 4	21 (67.7)
> 4	10 (32.3)
CA19-9
Positive	25 (87.1)
Negative	4 (12.9)
CEA
Positive	10 (32.3)
Negative	21 (67.7)
Clinical stage
IA	5 (16.1)
IB	6 (19.4)
IIA	6 (19.4)
IIB	5 (16.1)
III	6 (19.4)
IV	3 (9.7)
T classification
T1	5 (16.1)
T2	15 (48.4)
T3	9 (29.0)
T4	2 (6.5)
N classification
N0	21 (67.7)
N1	6 (19.4)
N2	4 (12.9)
Metastasis
M0	28 (90.3)
M1	3 (9.7)
Venous invasion
No	19 (61.3)
Yes	12 (38.7)
Lymphatic invasion
No	21 (67.7)
Yes	10 (32.3)
Expression of circ-LDLRAD3
Low expression	9 (29)
High expression	22 (71)

Table 5 Correlation between circ-LDLRAD3 expression and clinicopathological factors of pancreatic cancer patients (plasma samples)

Characteristic	Circ-LDLRAD3		P value
	Low or one, n	High, n
Age (yr)
≥ 60	5	10	0.609
< 60	4	12
Gender
Male	5	14	0.675
Female	4	8
Tumor diameter (cm)
≤ 4	6	15	0.935
> 4	3	7
CA19-9
Positive	6	21	0.030
Negative	3	1
CEA
Positive	5	5	0.076
Negative	4	17
Clinical stage
IA	3	2	0.060
IB	3	3
IIA	3	3
IIB	0	5
III	0	6
IV	0	3
T classification
T1	3	2	0.282
T2	3	12
T3	3	6
T4	0	2
N classification
N0	9	12	0.049
N1	0	6
N2	0	4
Metastasis
M0	9	19	0.244
M1	0	3
Venous invasion
No	9	10	0.005
Yes	0	12
Lymphatic invasion
No	9	12	0.014
Yes	0	10

Table 6 Correlation between circ-LDLRAD3 expression and clinicopathological factors of pancreatic cancer patients (ΔCT values in plasma samples)

Variable	Circ-LDLRAD3 expression level
	Spearman correlation	P value
Age (yr)	-0.108	0.562
Gender	0.059	0.752
Tumor diameter (cm)	-0.102	0.584
CA19-9	-0.398	0.027
CEA	-0.085	0.650
Clinical stage	-0.603	< 0.001
T classification	-0.129	0.491
N classification	-0.271	0.140
Metastasis	-0.5	0.004
Venous invasion	-0.392	0.029
Lymphatic invasion	-0.611	< 0.001